BNP Paribas Financial Markets Makes New $262,000 Investment in Sight Sciences, Inc. (NASDAQ:SGHT)

BNP Paribas Financial Markets purchased a new stake in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 71,896 shares of the company's stock, valued at approximately $262,000. BNP Paribas Financial Markets owned approximately 0.14% of Sight Sciences at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of SGHT. Long Focus Capital Management LLC boosted its position in Sight Sciences by 158.8% during the fourth quarter. Long Focus Capital Management LLC now owns 2,238,632 shares of the company's stock worth $8,149,000 after purchasing an additional 1,373,535 shares in the last quarter. Geode Capital Management LLC boosted its position in Sight Sciences by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 792,860 shares of the company's stock worth $2,887,000 after purchasing an additional 8,731 shares in the last quarter. B Group Inc. purchased a new stake in Sight Sciences during the fourth quarter worth $2,291,000. Renaissance Technologies LLC boosted its position in Sight Sciences by 654.3% during the fourth quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock worth $1,431,000 after purchasing an additional 340,906 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Sight Sciences by 2.1% during the fourth quarter. Northern Trust Corp now owns 332,491 shares of the company's stock worth $1,210,000 after purchasing an additional 6,727 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SGHT has been the topic of a number of research analyst reports. Piper Sandler decreased their target price on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Stifel Nicolaus cut their price target on Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Citigroup reissued a "neutral" rating and issued a $3.60 price target (up from $3.20) on shares of Sight Sciences in a report on Thursday, May 22nd. Lake Street Capital boosted their price target on Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a report on Friday, May 9th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $4.02.

Sight Sciences Trading Up 5.4%

Sight Sciences stock traded up $0.20 during trading on Monday, hitting $3.89. The company's stock had a trading volume of 178,391 shares, compared to its average volume of 214,836. The stock has a market capitalization of $201.10 million, a price-to-earnings ratio of -3.81 and a beta of 2.41. The stock's fifty day moving average is $2.91 and its 200 day moving average is $3.07. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.01. The firm had revenue of $17.51 million during the quarter, compared to analyst estimates of $16.51 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. As a group, equities research analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Insider Activity at Sight Sciences

In other Sight Sciences news, EVP Manohar K. Raheja bought 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was purchased at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the purchase, the executive vice president now owns 145,000 shares of the company's stock, valued at $395,850. This trade represents a 7.41% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Paul Badawi sold 24,174 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the completion of the transaction, the chief executive officer now owns 6,010,580 shares of the company's stock, valued at $13,824,334. The trade was a 0.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,196 shares of company stock worth $81,001. 30.90% of the stock is currently owned by insiders.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.